EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Benzinga · 10/16 17:45
EF Hutton analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.